Publicaciones en colaboración con investigadores/as de Mayo Clinic (12)

2024

  1. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

    Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306

2023

  1. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  2. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  3. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

  2. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

    Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178

2021

  1. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969

2020

  1. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

    British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802

  2. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740

2018

  1. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    Mayo Clinic Proceedings, Vol. 93, Núm. 3, pp. 307-320

2017

  1. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942

2009

  1. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

    Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403